Posiflex Wins Taiwan Excellence Award with All-In-One POS and Introduces an Exciting New Line of Kiosks
10.12.2020 04:00:00 EET | Business Wire | Press release
Posiflex Technology, Inc., a global leader in Point of Sale (POS), self-service kiosks, and embedded computing technologies. Posiflex has been focused on product applications of retail market trends and endeavors to improve users’ operational efficiency with cutting edge technology since its foundation in 1984. Posiflex is honored to receive the Taiwan Excellence Award 2021 for its innovative all-in-one Android POS, HS-3314A.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201209005001/en/
Posiflex's HS-3314A Wins Taiwan Excellence Awards 2021 (Photo: Business Wire)
The Ministry of Economic Affairs Taiwan established the Taiwan Excellence Awards in 1993. Eligible candidates are subjected to cover four major aspects of “R&D”, “Design”, “Quality” and “Marketing” to identify outstanding products that offer “Innovative Value” while being “made in Taiwan”. Products that have been selected for the Taiwan Excellence Awards would serve as examples of the domestic industries and be promoted by the government internationally to shape the creative image for Taiwanese businesses.
The HS-3314A series is a 14” Android 9.0 PCAP touch POS system with a built-in printer and designed with the high-performance Rockchip RK3399 platform and various peripherals. Built with unique innovation and a compact body, HS-3314A is equipped with a high-speed, detachable thermal receipt printer. Its innovative screwless and modular design not only makes installation simple and maintenance easy but also allows for a variety of peripherals including a secondary display, MSR, fingerprint sensor, and barcode scanner. The whole system greatly improves retailer operation and work efficiency with space-saving design and reduced downtime.
Not only has Posiflex been building the best POS systems for the retail industry, but it is also in sync with the rapid rise of self-service technology. As the world has been deeply affected by the COVID-19 outbreak, it has unleashed a demand for safety-conscious products such as self-service kiosks. Posiflex introduces the new Mercury EK Series to its sophisticated self-service solutions to help operators succeed with the rising need for the self-service kiosk. Built to be compact and functional, the Mercury EK Series is available in 15” PCAP touch screen in landscape mode while 15.6” & 21.5” touch screens are available in both landscape and portrait mode. Designed with flexibility in mind, the Mercury EK Series can deploy as either countertop or floor-standing as well as customizable with peripherals including NFC/RFID reader, fingerprint sensor, 2D scanner, status indicator, and an EMV payment device. The versatility of the Mercury EK Series allows retailers to customize as their businesses need. They are also engineered for single-user assembly and ease of maintenance, thus reducing costs of deployment and service. With all the flexibility and user-friendly features, the Mercury EK Series can serve as an extension of employees, handling mundane tasks while allowing employees to focus on providing better customer service, therefore creating more demand and business for retailers.
With the award-winning all-in-one POS HS-3314A and the small-footprint kiosk Mercury EK Series, Posiflex provides POS/Kiosk solutions with variety and quality for the retail industry to meet customers’ various demands as well as create exceptional consumer experiences.
About Posiflex Group:
Posiflex has designed and manufactured world-class POS solutions for more than 30 years. Since 2016, the company has acquired KIOSK and Portwell, further expanding into self-service and embedded PC offerings. The global Posiflex Group is in place to provide world-class B2B Serviced IoT solutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005001/en/
Contact information
Posiflex Group Press: Brad Chou, marketing@posiflex.com.tw
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom